ELDN
NASDAQ · Biotechnology
Eledon Pharmaceuticals Inc
$2.37
-0.31 (-11.42%)
Open$2.65
Previous Close$2.67
Day High$2.65
Day Low$2.36
52W High$4.49
52W Low$1.35
Volume—
Avg Volume1.07M
Market Cap211.69M
P/E Ratio—
EPS$-0.96
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+411.2% upside
Current
$2.37
$2.37
Target
$12.09
$12.09
$9.42
$12.09 avg
$15.53
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 30.92M | 31.36M | 28.49M |
| Net Income | 5.14M | 5.83M | 4.48M |
| Profit Margin | 16.6% | 18.6% | 15.7% |
| EBITDA | 8.25M | 8.46M | 8.04M |
| Free Cash Flow | 7.08M | 5.83M | 4.28M |
| Rev Growth | +12.9% | -8.9% | -3.6% |
| Debt/Equity | 0.35 | 0.38 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |